乾癬性関節炎（PsA）治療薬の世界市場の予測 - 疫学・パイプライン分析（2022年～2027年）

世界の乾癬性関節炎（PsA）治療薬の市場規模は、2022年～2027年にCAGRで8.09%の成長が予測されています。乾癬性関節炎の流行が、市場の成長を促進しています。推定によると、欧州連合では2014年に200万人超がPsAに罹患しています。

当レポートでは、世界の乾癬性関節炎（PsA）治療薬市場について調査分析し、市場動向、市場の促進要因と成長機会についてのデータ、セグメント分析、企業プロファイルなどを提供しています。

目次

第1章 乾癬性関節炎の概要

第2章 乾癬性関節炎の疫学と概要

• 主要8市場の乾癬性関節炎の発生率と有病率の実績と予測の数量
• 主要8市場の乾癬性関節炎の発生率と有病率の比較分析
• 主要8市場の乾癬性関節炎の発生率の実績と予測の数量：疾患タイプ別
• 主要8市場の乾癬性関節炎の発生率の実績と予測の数量：重症度タイプ別
• 主要8市場の乾癬性関節炎の発生率の実績と予測の数量：性別・年齢層別
• 主要8市場の乾癬性関節炎の有病率の実績と予測の数量：疾患タイプ別
• 主要8市場の乾癬性関節炎の症例の有病率の実績と予測の数量：重症度タイプ別
• 主要8市場の乾癬性関節炎の症例の有病率の実績と予測の数量：性別・年齢層別
• 米国の乾癬性関節炎の発生率と有病率の実績と予測の数量
• 米国の乾癬性関節炎の発生率と有病率の比較分析
• 米国の乾癬性関節炎の発生率の実績と予測の数量：疾患タイプ別
• 米国の乾癬性関節炎の症例の発生率の実績と予測の数量：重症度タイプ別
• 米国の乾癬性関節炎の症例の実績と予測の数量：性別・年齢層別
• 米国の乾癬性関節炎の症例の有病率の実績と予測の数量：疾患タイプ別
• 米国の乾癬性関節炎の症例の有病率の実績と予測の数量：重症度タイプ別
• 米国の乾癬性関節炎の症例の有病率の実績と予測の数量：性別・年齢層別
• 中国の乾癬性関節炎の発生率と有病率の実績と予測の数量
• 中国の乾癬性関節炎の発生率と有病率の比較分析
• 中国の乾癬性関節炎の発生率の実績と予測の数量：疾患タイプ別
• 中国の乾癬性関節炎の症例の発生率の実績と予測の数量：重症度タイプ別
• 中国の乾癬性関節炎の発生率の実績と予測の数量：性別・年齢層別
• 中国の乾癬性関節炎の症例の有病率の実績と予測の数量：疾患タイプ別
• 中国の乾癬性関節炎の症例の有病率の実績と予測の数量：重症度タイプ別
• 中国の乾癬性関節炎の有病率の実績と予測の数量：性別・年齢層別
• 日本の乾癬性関節炎の発生率と有病率の実績と予測の数量
• 日本の乾癬性関節炎の発生率と有病率の比較分析
• 日本の乾癬性関節炎の発生率の実績と予測の数量：疾患タイプ別
• 日本の乾癬性関節炎の発生率の実績と予測の数量：重症度タイプ別
• 日本の乾癬性関節炎の症例の実績と予測の数量：性別・年齢層別
• 日本の乾癬性関節炎の症例の有病率の実績と予測の数量：疾患タイプ別
• 日本の乾癬性関節炎の有病率の実績と予測の数量：重症度タイプ別
• 日本の乾癬性関節炎の有病率の実績と予測の数量：性別・年齢層別
• ドイツの乾癬性関節炎の発生率と有病率の実績と予測の数量
• ドイツの乾癬性関節炎の発生率と有病率の比較分析
• ドイツの乾癬性関節炎の発生率の実績と予測の数量：疾患タイプ別
• ドイツの乾癬性関節炎の症例の発生率の実績と予測の数量：重症度タイプ別
• ドイツの乾癬性関節炎の発生率の実績と予測の数量：性別・年齢層別
• ドイツの乾癬性関節炎の症例の有病率の実績と予測の数量：疾患タイプ別
• ドイツの乾癬性関節炎の症例の有病率の実績と予測の数量：重症度タイプ別
• ドイツの乾癬性関節炎の有病率の実績と予測の数量：性別・年齢層別
• 英国の乾癬性関節炎の発生率と有病率の実績と予測の数量
• 英国の乾癬性関節炎の発生率と有病率の比較分析
• 英国の乾癬性関節炎の症例の発生率の実績と予測の数量：疾患タイプ別
• 英国の乾癬性関節炎の症例の発生率の実績と予測の数量：重症度タイプ別
• 英国の乾癬性関節炎の症例の実績と予測の数量：性別・年齢層別
• 英国の乾癬性関節炎の症例の有病率の実績と予測の数量：疾患タイプ別
• 英国の乾癬性関節炎の症例の有病率の実績と予測の数量：重症度タイプ別
• 英国の乾癬性関節炎の症例の有病率の実績と予測の数量：性別・年齢層別
• フランスの乾癬性関節炎の発生率と有病率の実績と予測の数量
• フランスの乾癬性関節炎の発生率と有病率の比較分析
• フランスの乾癬性関節炎の発生率の実績と予測の数量：疾患タイプ別
• フランスの乾癬性関節炎の発生率の実績と予測の数量：重症度タイプ別
• フランスの乾癬性関節炎の発生率の実績と予測の数量：性別・年齢層別
• フランスの乾癬性関節炎の症例の有病率の実績と予測の数量：疾患タイプ別
• フランスの乾癬性関節炎の症例の有病率の実績と予測の数量：重症度タイプ別
• フランスの乾癬性関節炎の有病率の実績と予測の数量：性別・年齢層別
• イタリアの乾癬性関節炎の発生率と有病率の実績と予測の数量
• イタリアの乾癬性関節炎の発生率と有病率の比較分析
• イタリアの乾癬性関節炎の発生率の実績と予測の数量：疾患タイプ別
• イタリアの乾癬性関節炎の症例の発生率の実績と予測の数量：重症度タイプ別
• イタリアの乾癬性関節炎の発生率の実績と予測の数量：性別・年齢層別
• イタリアの乾癬性関節炎の症例の有病率の実績と予測の数量：疾患タイプ別
• イタリアの乾癬性関節炎の症例の有病率の実績と予測の数量：重症度タイプ別
• イタリアの乾癬性関節炎の症例の有病率の実績と予測の数量：性別・年齢層別
• スペインの乾癬性関節炎の発生率と有病率の実績と予測の数量
• スペインの乾癬性関節炎の発生率と有病率の比較分析
• スペインの乾癬性関節炎の発生率の実績と予測の数量：疾患タイプ別
• スペインの乾癬性関節炎の発生率の実績と予測の数量：重症度タイプ別
• スペインの乾癬性関節炎の発生率の実績と予測の数量：性別・年齢層別
• スペインの乾癬性関節炎の症例の有病率の実績と予測の数量：疾患タイプ別
• スペインの乾癬性関節炎の症例の有病率の実績と予測の数量：重症度タイプ別
• スペインの乾癬性関節炎の症例の有病率の実績と予測の数量：性別・年齢層別

第3章 乾癬性関節炎の市場規模と概要

• 主要8市場の乾癬性関節炎の実績と予測の収益
• 主要8市場の乾癬性関節炎の実績と予測の収益のスナップショット
• 主要8市場の乾癬性関節炎の主な承認薬
• 主要8市場の実績と予測の収益：性別タイプ・疾患タイプ・重症度・年齢層・薬品クラス別
• 米国の乾癬性関節炎の実績と予測の収益
• 米国の乾癬性関節炎の実績と予測の収益のスナップショット
• 米国の実績と予測の収益：性別タイプ・疾患タイプ・重症度・年齢層・薬品クラス別
• 中国の乾癬性関節炎の過去の収益と予測される収益
• 中国の乾癬性関節炎の実績と予測の収益のスナップショット
• 中国の実績と予測の収益：性別タイプ・疾患タイプ・重症度・年齢層・薬品クラス別
• 日本の乾癬性関節炎の売上高の実績と予測
• 日本の乾癬性関節炎の実績と予測の収益のスナップショット
• 日本の実績と予測の収益：性別タイプ・疾患タイプ・重症度・年齢層・薬品クラス別
• ドイツの乾癬性関節炎の実績と予測の収益
• ドイツの乾癬性関節炎の実績と予測の収益のスナップショット
• ドイツの実績と予測の収益：性別タイプ・疾患タイプ・重症度・年齢層・薬品クラス別
• 英国の乾癬性関節炎の実績と予測の収益
• 英国の乾癬性関節炎の実績と予測の収益のスナップショット
• 英国の実績と予測の収益：性別タイプ・疾患タイプ・重症度・年齢層・薬品クラス別
• フランスの乾癬性関節炎の実績と予測の収益
• フランスの乾癬性関節炎の実績と予測の収益のスナップショット
• フランスの実績と予測の収益：性別タイプ・疾患タイプ・重症度・年齢層・薬品クラス別
• イタリアの乾癬性関節炎の実績と予測の収益
• イタリアの乾癬性関節炎の実績と予測の収益のスナップショット
• イタリアの実績と予測の収益：性別タイプ・疾患タイプ・重症度・年齢層・薬品クラス別
• スペインの乾癬性関節炎の実績と予測の収益
• スペインの乾癬性関節炎の実績と予測の収益のスナップショット
• スペインの実績と予測の収益：性別タイプ・疾患タイプ・重症度・年齢層・薬品クラス別

第4章 乾癬性関節炎の上市薬品の概要

• 乾癬性関節炎の上市薬品 - 概要
• 乾癬性関節炎の上市薬品 - 要約

第5章 乾癬性関節炎のパイプライン薬品の概要

• 乾癬性関節炎パイプライン薬品 - 概要
• 乾癬性関節炎パイプライン薬品 - スナップショット
• 乾癬性関節炎パイプライン薬品の概要とスナップショット - 疾患タイプ別
• 乾癬性関節炎パイプライン薬品の概要とスナップショット - 開発段階別
• 乾癬性関節炎パイプライン薬品の概要とスナップショット - 投与経路別
• 乾癬性関節炎パイプライン薬品の概要とスナップショット - 作用機序別
• 乾癬性関節炎パイプライン薬品の概要とスナップショット - 分子タイプ別
• 乾癬性関節炎パイプライン薬品の概要とスナップショット - 地域タイプ別

第6章 乾癬性関節炎の臨床試験の概要

• 乾癬性関節炎の臨床試験の概要スナップショット
• 乾癬性関節炎の臨床試験の概要 - 採用状況別
• 乾癬性関節炎の臨床試験の概要 - 製品タイプ別
• 乾癬性関節炎の臨床試験の概要 - 投与経路別
• 乾癬性関節炎の臨床試験の概要 - 分子タイプ別
• 乾癬性関節炎の臨床試験の概要 - 地域タイプ別

第7章 乾癬性関節炎の市場力学

• 乾癬性関節炎治療薬市場の促進要因
• 乾癬性関節炎治療薬市場の抑制要因
• 乾癬性関節炎治療薬市場の動向

第8章 乾癬性関節炎の競合情勢

• 乾癬性関節炎の競合情勢 - 上市薬品
• 主要企業プロファイル
• その他の主要企業プロファイル
• 乾癬性関節炎治療薬市場の競合シナリオ
• 主要企業プロファイルのスナップショット
• その他の主要企業プロファイルのスナップショット
• 乾癬性関節炎の競合情勢 - パイプライン薬品
• 主な新興企業プロファイル
• その他の主な新興企業プロファイル
• 主要企業プロファイルのスナップショット

第9章 乾癬性関節炎のその他

• 主な暫定的な薬品承認のタイムライン
• 主な規制指定
• 主なマイルストーン
• 取引と提携
• 非アクティブ/生産終了/休止中の製品

第10章 付録

LIST OF EXHIBITS

Exhibit 1: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 2: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN 8 MAJOR MARKETS (2018 - 2020)

Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 4: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 5: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 6: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 7: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 8: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 9: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 10: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 11: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 12: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN US (2018 - 2027)

Exhibit 13: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN US (2018 - 2020)

Exhibit 14: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN US (2021 - 2027)

Exhibit 15: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN US (2018 - 2027)

Exhibit 16: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN US (2018 - 2027)

Exhibit 17: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN US (2018 - 2027)

Exhibit 18: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN US (2018 - 2027)

Exhibit 19: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN US (2018 - 2027)

Exhibit 20: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN US (2018 - 2027)

Exhibit 21: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN US (2018 - 2027)

Exhibit 22: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN US (2018 - 2027)

Exhibit 23: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN CHINA (2018 - 2027)

Exhibit 24: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN CHINA (2018 - 2020)

Exhibit 25: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN CHINA (2021 - 2027)

Exhibit 26: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN CHINA (2018 - 2027)

Exhibit 27: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN CHINA (2018 - 2027)

Exhibit 28: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN CHINA (2018 - 2027)

Exhibit 29: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN CHINA (2018 - 2027)

Exhibit 30: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN CHINA (2018 - 2027)

Exhibit 31: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN CHINA (2018 - 2027)

Exhibit 32: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN CHINA (2018 - 2027)

Exhibit 33: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN CHINA (2018 - 2027)

Exhibit 34: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN JAPAN (2018 - 2027)

Exhibit 35: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN JAPAN (2018 - 2020)

Exhibit 36: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN JAPAN (2021 - 2027)

Exhibit 37: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN JAPAN (2018 - 2027)

Exhibit 38: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN JAPAN (2018 - 2027)

Exhibit 39: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN JAPAN (2018 - 2027)

Exhibit 40: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN JAPAN (2018 - 2027)

Exhibit 41: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN JAPAN (2018 - 2027)

Exhibit 42: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN JAPAN (2018 - 2027)

Exhibit 43: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORITIC ARTHRITIS BY AGE GROUP IN JAPAN (2018 - 2027)

Exhibit 44: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN JAPAN (2018 - 2027)

Exhibit 45: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN GERMANY (2018 - 2027)

Exhibit 46: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN GERMANY (2018 - 2020)

Exhibit 47: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN GERMANY (2021 - 2027)

Exhibit 48: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN GERMANY (2018 - 2027)

Exhibit 49: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN GERMANY (2018 - 2027)

Exhibit 50: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIAYTIC ARTHRITIS BY AGE GROUP IN GERMANY (2018 - 2027)

Exhibit 51: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN GERMANY (2018 - 2027)

Exhibit 52: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN GERMANY (2018 - 2027)

Exhibit 53: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN GERMANY (2018 - 2027)

Exhibit 54: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN GERMANY (2018 - 2027)

Exhibit 55: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN GERMANY (2018 - 2027)

Exhibit 56: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN UK (2018 - 2027)

Exhibit 57: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN UK (2018 - 2020)

Exhibit 58: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN UK (2021 - 2027)

Exhibit 59: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN UK (2018 - 2027)

Exhibit 60: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN UK (2018 - 2027)

Exhibit 61: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN UK (2018 - 2027)

Exhibit 62: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN UK (2018 - 2027)

Exhibit 63: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN UK (2018 - 2027)

Exhibit 64: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN UK (2018 - 2027)

Exhibit 65: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN UK (2018 - 2027)

Exhibit 66: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN UK (2018 - 2027)

Exhibit 67: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN FRANCE (2018 - 2027)

Exhibit 68: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN FRANCE (2018 - 2020)

Exhibit 69: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN FRANCE (2021 - 2027)

Exhibit 70: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN FRANCE (2018 - 2027)

Exhibit 71: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN FRANCE (2018 - 2027)

Exhibit 72: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN FRANCE (2018 - 2027)

Exhibit 73: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN FRANCE (2018 - 2027)

Exhibit 74: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN FRANCE (2018 - 2027)

Exhibit 75: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN FRANCE (2018 - 2027)

Exhibit 76: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN FRANCE (2018 - 2027)

Exhibit 77: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN FRANCE (2018 - 2027)

Exhibit 78: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN ITALY (2018 - 2027)

Exhibit 79: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN ITALY (2018 - 2020)

Exhibit 80: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN ITALY (2021 - 2027)

Exhibit 81: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN ITALY (2018 - 2027)

Exhibit 82: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN ITALY (2018 - 2027)

Exhibit 83: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN ITALY (2018 - 2027)

Exhibit 84: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN ITALY (2018 - 2027)

Exhibit 85: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN ITALY (2018 - 2027)

Exhibit 86: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN ITALY (2018 - 2027)

Exhibit 87: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN ITALY (2018 - 2027)

Exhibit 88: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN ITALY (2018 - 2027)

Exhibit 89: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN SPAIN (2018 - 2027)

Exhibit 90: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN SPAIN (2018 - 2020)

Exhibit 91: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN SPAIN (2021 - 2027)

Exhibit 92: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN SPAIN (2018 - 2027)

Exhibit 93: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN SPAIN (2018 - 2027)

Exhibit 94: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN SPAIN (2018 - 2027)

Exhibit 95: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN SPAIN (2018 - 2027)

Exhibit 96: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN SPAIN (2018 - 2027)

Exhibit 97: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN SPAIN (2018 - 2027)

Exhibit 98: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN SPAIN (2018 - 2027)

Exhibit 99: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN SPAIN (2018 - 2027)

Exhibit 100: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 101: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN 8 MAJOR MARKETS (2018 - 2020)

Exhibit 102: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 103: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 104: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 105: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 107: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN US (2021 - 2027)

Exhibit 107: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN US (2018 - 2020)

Exhibit 108: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN US (2021 - 2027)

Exhibit 109: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN US (2021 - 2027)

Exhibit 110: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN US (2021 - 2027)

Exhibit 111: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN US (2021 - 2027)

Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN US (2021 - 2027)

Exhibit 112: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN CHINA (2021 - 2027)

Exhibit 113: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN CHINA (2018 - 2020)

Exhibit 114: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN CHINA (2021 - 2027)

Exhibit 115: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN CHINA (2021 - 2027)

Exhibit 116: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN CHINA (2021 - 2027)

Exhibit 117: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN CHINA (2021 - 2027)

Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN CHINA (2021 - 2027)

Exhibit 118: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN GERMANY (2021 - 2027)

Exhibit 119: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN GERMANY (2018 - 2020)

Exhibit 120: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN GERMANY (2021 - 2027)

Exhibit 121: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN GERMANY (2021 - 2027)

Exhibit 122: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN GERMANY (2021 - 2027)

Exhibit 123: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN GERMANY (2021 - 2027)

Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN GERMANY (2021 - 2027)

Exhibit 124: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN JAPAN (2021 - 2027)

Exhibit 125: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN JAPAN (2018 - 2020)

Exhibit 126: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN JAPAN (2021 - 2027)

Exhibit 127: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN JAPAN (2021 - 2027)

Exhibit 128: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN JAPAN (2021 - 2027)

Exhibit 129: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN JAPAN (2021 - 2027)

Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN JAPAN (2021 - 2027)

Exhibit 130: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN FRANCE (2021 - 2027)

Exhibit 131: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN FRANCE (2018 - 2020)

Exhibit 132: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN FRANCE (2021 - 2027)

Exhibit 133: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN FRANCE (2021 - 2027)

Exhibit 134: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN FRANCE (2021 - 2027)

Exhibit 135: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN FRANCE (2021 - 2027)

Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN FRANCE (2021 - 2027)

Exhibit 136: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN ITALY (2021 - 2027)

Exhibit 137: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN ITALY (2018 - 2020)

Exhibit 138: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN ITALY (2021 - 2027)

Exhibit 139: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN ITALY (2021 - 2027)

Exhibit 140: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN ITALY (2021 - 2027)

Exhibit 141: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN ITALY (2021 - 2027)

Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN ITALY (2021 - 2027)

Exhibit 142: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN UK (2021 - 2027)

Exhibit 143: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN UK (2018 - 2020)

Exhibit 144: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN UK (2021 - 2027)

Exhibit 145: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN UK (2021 - 2027)

Exhibit 146: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN UK (2021 - 2027)

Exhibit 147: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN UK (2021 - 2027)

Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN UK (2021 - 2027)

Exhibit 148: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN SPAIN (2021 - 2027)

Exhibit 149: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN SPAIN (2018 - 2020)

Exhibit 150: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN SPAIN (2021 - 2027)

Exhibit 151: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN SPAIN (2021 - 2027)

Exhibit 152: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN SPAIN (2021 - 2027)

Exhibit 153: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN SPAIN (2021 - 2027)

Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN SPAIN (2021 - 2027)

Exhibit 154: MARKETED DRUGS OVERVIEW IN PSORIATIC ARTHRITIS MARKET

Exhibit 155: MARKETED DRUGS OVERVIEW SNAPSHOT IN PSORIATIC ARTHRITIS TREATMENT

Exhibit 156: PIPELINE DRUGS OVERVIEW IN PSORIATIC ARTHRITIS TREATMENT MARKET

Exhibit 157: PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW BY DISEASE TYPE

Exhibit 158: PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE

Exhibit 159: PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION

Exhibit 160: PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION

Exhibit 161: PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE

Exhibit 162: PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE

Exhibit 163: PSORIATIC ARTHRITIS CLINICAL TRIAL ANALYSIS SNAPSHOT

Exhibit 164: PSORIATIC ARTHRITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY RECRUITMENT STATUS

Exhibit 165: PSORIATIC ARTHRITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY PRODUCT TYPE

Exhibit 166: PSORIATIC ARTHRITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY ROUTE OF ADMINISTRATION

Exhibit 167: PSORIATIC ARTHRITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY MOLECULE TYPE

Exhibit 168: PSORIATIC ARTHRITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY GEOGRAPHY TYPE

Exhibit 169: COMPETITIVE ASSESSMENT OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET

LIST OF TABLES

Table 1: KEY MARKET DRIVERS IN PSORIATIC ARTHRITIS MARKET

Table 2: KEY MARKET CONSTRAINTS IN PSORIATIC ARTHRITIS MARKET

Table 3: KEY MARKET TRENDS IN PSORIATIC ARTHRITIS TREATMENT MARKET

Table 4: KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUGS IN PSORIATIC ARTHRITIS

Table 5: KEY REGULATORY DESIGNATIONS OF PIPELINE DRUGS IN PSORIATIC ARTHRITIS

Table 6: KEY MILESTONES IN PSORIATIC ARTHRITIS MARKET

Table 7: KEY DEALS & COLLABORATIONS IN PSORIATIC ARTHRITIS MARKET

Table 8: KEY INACTIVE/DISCONTINUED PRODUCTS IN PSORIATIC ARTHRITIS TREATMENT

The global psoriatic arthritis treatment market is expected to grow at a CAGR of 8.09% during 2022-2027.

MARKET INSIGHTS

Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation. Psoriatic arthritis occurs in up to 30% of patients with psoriasis, most commonly those aged between 30 and 60 years. It starts about 10 years after psoriasis develops for many people, but some develop PsA first or without ever developing or noticing psoriasis. PsA can occur at any age and affects men and women equally. In recent years, women have contributed more to the global psoriatic arthritis treatment market as they are at greater risk of developing psoriatic arthritis. According to estimates, in the European Union, PsA affects more than 2 million people, and in the United States, about 0.5 million.

The exact cause of PsA is not yet known. Family history plays a strong role; about 40% of those with the disease have a family member with psoriasis or arthritis. Risk factors can include obesity, severe psoriasis, nail disease, and trauma or deep lesions at sites of trauma.

• Psoriatic Arthritis Diagnosis:

There's no specific test to diagnose psoriatic arthritis. The symptoms are similar to other arthritic diseases such as rheumatoid arthritis, reactive arthritis, and gout. Imaging techniques such as X-rays, CT scans, ultrasound, MRI, and skin biopsies may all be used for diagnosis.

• Psoriatic Arthritis Treatment:

Treatment depends on the extent of pain, swelling, and stiffness. Those with very mild arthritis may require treatment only when their joints are painful and may stop therapy when they feel better. The major types of treatment for psoriatic arthritis are Non-steroidal anti-inflammatory drugs such as ibuprofen (Motrin or Advil) or naproxen (Aleve) as initial treatment. If arthritis does not respond, disease-modifying anti-rheumatic drugs may be prescribed. These include sulfasalazine (Azulfidine), methotrexate (Rheumatrex, Trexall, Otrexup, Rasuvo), cyclosporine (Neoral, Sandimmune, Gengraf), and leflunomide. Sometimes combinations of these drugs may be used together. Azathioprine (Imuran) may help those with severe forms of PSA.

Other treatments include biologics, typically starting with TNF inhibitors such as adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade). Other biologics used for PsA include the IL-17A inhibitors secukinumab (Cosentyx) and ixekizumab (Taltz); IL-12/23 inhibitor ustekinumab (Stelara); IL-23 inhibitors risankizumab-rzaa (Skyrizi) and guselkumab (Tremfya) or other classes abatacept (Orencia). Newer oral medications, such as tofacitinib (Xeljanz), upadacitinib (Rinvoq), and apremilast (Otezla), have also been shown to be effective.

KEY HIGHLIGHTS

The psoriatic arthritis treatment market portfolio contains a total of 25+ assets that are in various phases of development. Most industry-sponsored drugs in active clinical development for psoriatic arthritis are in the Phase III stage. The emerging therapeutics for psoriatic arthritis include Bimekizumab, Tildrakizumab, SHR-0302, Neihulizumab, and many others. Launching these novel emerging drugs will shift the PsA treatment paradigm in the near future. With more than 25 molecules in various stages of development, it is expected that new vendors are likely to enter the industry with a novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating psoriatic arthritis.

• Psoriatic Arthritis: Clinical Trials Scenario

The clinical trial portfolio contains 150+ trials in various development phases. Most industry-sponsored drugs in active clinical development for PsA are in the Phase III stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for psoriatic arthritis have been in the late phase of development, with 58% of trials in Phase II/III & III and only 41% in Phase Phase I-II.

MARKET DRIVERS & TRENDS

• Increasing Adoption of Biological Therapies

Biological therapies such as anti-tumor necrosis factor (TNF) and anti-interleukin antibodies are widely used in the psoriatic arthritis treatment market. With Stelara being biologic approved for PsA in 2013, there is a demand for therapies with novel MOAs that are less immunogenic than current offerings. Many new classes of therapies are looking to enter the psoriatic arthritis treatment market over the next few years. The biologics such as interleukin inhibitors are making inroads into the psoriatic arthritis market owing to better clinical profile and convenient patient dosing.

• Anticipated Launch of Emerging Drugs

A recent wave of biologic products prescribed for psoriatic arthritis treatment will likely create lucrative opportunities. Despite the plethora of therapies currently available to patients with psoriatic arthritis (PsA), there is still room for improvement within the psoriatic arthritis treatment market space.

Arizton anticipates the launch of five new agents among the 8MM, including two interleukins (IL) inhibitors (Bimekizumab; Tildrakizumab) and two oral Janus kinase (JAK) inhibitors (Filgotinib and SHR0302) and one oral tyrosine kinase 2 (TYK2) inhibitor (Deucravacitinib). Launching these late-stage drugs will create an opportunity for growth in the global psoriatic arthritis treatment market.

• Focus on Novel Drugs with Novel Mechanism

Over the past seven years, agents that block inflammatory pathways other than tumor necrosis factor (TNF) represent new options for treating psoriasis arthritis (PsA). The therapeutic agents targeting the IL-23/IL-17 axis have been proven to be very effective in psoriatic arthritis, some are already in the therapeutic armamentarium, and others are in development. IL-23/IL-17 axis cytokines are essential players in the pathogenesis of psoriasis and PsA. Inhibition of IL-23 and IL-17 with monoclonal antibodies is a very effective therapy in the psoriatic arthritis treatment market. Over the next five years, Arizton expects to see a surge of innovation emerging from the research and development pipeline and a range of technology-enabled transformations that will expand the evidence-basis for interventions and bring measurable improvements to outcomes.

SEGMENTATION ANALYSIS

• Drug Class: TNF-Alpha inhibitors account for a significant share of the global psoriatic arthritis treatment market. However, interleukin inhibitors are expected to be the fastest growing segment during the forecast period. Recently approved interleukin inhibitors such as Skyrizi (risankizumab-rzaa) and Cosentyx (Secukinumab) are expected to drive the global psoriatic arthritis treatment market during the forecast period.

Segmentation by Drug Class

• TNF Inhibitors
• Interleukin Inhibitors
• NSAIDs
• Other classes of Drugs
• Gender Type: Women accounted for a significant share of the global psoriatic arthritis treatment market under the gender type segment. This is because women have been at greater risk of psoriatic arthritis in recent years.

Segmentation by Gender Type

• Men
• Women
• Disease Type: Enthesitis is expected to account for a significant share. However, Dactylitis is expected to be the fastest growing segment during the forecast period.

Segmentation by Disease Type

• Spondylitis
• Enthesitis
• Dactylitis
• Age Group: People aged 50 years and below are expected to account for a significant share of the global psoriatic arthritis treatment market.

Segmentation by Age Group

• 50 years and Below
• 50 years and Above
• Severity Type: People with mild form are expected to account for a significant share of the global psoriatic arthritis treatment market under the severity type category. However, people with moderate form are expected to be the fastest growing segment during the forecast period.

Segmentation by Severity Type

• Moderate
• Mild
• Severe

GEOGRAPHICAL OUTLOOK

The U.S. dominates the global psoriatic arthritis treatment market by geography due to the healthcare affordability in the U.S., the knowledge and awareness amongst the people, and the technological advancement in this region. However, Germany is expected to grow faster with a high CAGR in the PsA drug industry due to the rise in access and quality of healthcare, increased awareness about disease management, and rising healthcare expenditure in this region. The trend of biosimilars in emerging markets, such as China and Japan, could potentially alter this region's psoriatic arthritis therapeutic landscape.

According to Arizton estimates, the prevalent cases of psoriatic arthritis were high in China, followed by Spain and the U.K. in 2020. The increasing prevalence of psoriatic arthritis is driving the growth of the psoriatic arthritis treatment market. According to estimates, more than two million people in European Union were affected by PsA in 2014.

Segmentation by Geography

• North America
  • United States
• APAC
  • China
  • Japan
• Europe
  • U.K.
  • France
  • German
  • Italy
  • Spain

COMPETITIVE LANDSCAPE

The global psoriatic arthritis treatment market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating PsA. The U.S. Food and Drug Administration (FDA) approved the interleukin antibody Stelara (Ustekinumab) for treating psoriatic arthritis in 2013. Recently the FDA approved interleukins such as Skyrizi (risankizumab-rzaa) in 2022 and Cosentyx (secukinumab) in 2021 for treating PsA. Although generic products continue to capture significant psoriatic arthritis treatment market share, the arrival of biologics and other targeted therapies indicate a paradigm shift in this therapeutic space through the forecast period.

Companies such as AbbVie Inc., Johnson & Johnson, Takeda Pharmaceutical Co Ltd, Biogen Inc, UCB SA, Amgen, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, and Novartis are the major players in the global psoriatic arthritis treatment market. These players are focused on adopting growth strategies to strengthen their product portfolio. These companies have adopted strategies such as collaborations & acquisitions, expansion of geographical footprint, investments in research & development, and manufacture of novel drugs to compete in the global psoriatic arthritis treatment market.

The other prominent players operating in the psoriatic arthritis treatment market include Sun Pharmaceuticals, Bausch Health Companies Inc, Jiangsu HengRui Medicine Co. Ltd, Biocad Biopharmaceutical, Meiji Holdings Co Ltd, and Bio-Thera. These players are focused on R&D initiatives for developing technologically advanced and innovative psoriatic drugs and are also entering collaborations to maintain their position in the industry.

Key Vendors

• AbbVie Inc.
• Johnson & Johnson
• UCB SA
• Amgen
• Bristol-Myers Squibb
• Pfizer
• Eli Lilly and Company
• Novartis

Other Prominent Vendors

• Samsung Bioepis
• Boehringer Ingelheim
• Mylan
• Merck & Co., Inc
• Coherus BioSciences, Inc

Key Emerging Vendors with Late Stage Pipeline Drugs

• Sun Pharmaceuticals
• Bausch Health Companies Inc
• Jiangsu HengRui Medicine Co. Ltd
• Biocad Biopharmaceutical
• Meiji Holdings Co Ltd
• Bio-Thera

REPORT COVERS

• Detailed overview of psoriatic arthritis treatment market, including disease definition, classification, diagnosis, and treatment pattern.
• Overview of the global trends of the psoriatic arthritis treatment market in the eight major markets (8MM)
• Historical, current, and projected patient pool of PsA in the eight major markets (8MM) for the 2018 - 2027 period
• In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
• Psoriatic arthritis treatment market share of the market players, company profiles, product specifications, and competitive landscape
• Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
• Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities.
• Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for PsA across the complete product development cycle, including all clinical and non-clinical stages
• Detailed overview of clinical trial activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and geography type for psoriatic arthritis across all clinical stages
• Coverage of dormant and discontinued pipeline projects along with the reasons across PsA
• Coverage of significant milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the psoriatic arthritis treatment market.

KEY QUESTIONS ANSWERED

• 1. How big is the global psoriatic arthritis treatment market?
• 2. What is the growth rate of the global psoriatic arthritis treatment market?
• 3. What factors drive the growth of the psoriatic arthritis treatment market?
• 4. Who are the leading vendors operating in the psoriatic arthritis treatment market?
• 5. Which region holds the largest share in the global psoriatic arthritis treatment market?

TABLE OF CONTENTS

• 1. PSORIATIC ARTHRITIS OVERVIEW
• 1.1. Psoriatic Arthritis Disease - An Overview
• 2. PSORIATIC ARTHRITIS EPIDEMIOLOGY & OVERVIEW
• 2.1. 8MM: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
• 2.2. 8MM: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
• 2.3. 8MM: Historic & Projected Volume of incidence of Psoriatic Arthritis cases by Disease Type
• 2.4. 8MM: Historic & Projected Volume of incidence of Psoriatic Arthritis cases by Severity Type
• 2.5. 8MM: Historic & Projected Volume of Incidence of Psoriatic Arthritis cases by Gender & Age Group
• 2.6. 8MM: Historic & Projected Volume of Prevalence of Psoriatic Arthritis cases by Disease type
• 2.7. 8MM: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
• 2.8. 8MM: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.9. US: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
• 2.10. US: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
• 2.11. US: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
• 2.12. US: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
• 2.13. US: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.14. US: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
• 2.15. US: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
• 2.16. US: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.17. China: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
• 2.18. China: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
• 2.19. China: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
• 2.20. China: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
• 2.21. China: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.22. China: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
• 2.23. China: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
• 2.24. China: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.25. Japan: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
• 2.26. Japan: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
• 2.27. Japan: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
• 2.28. Japan: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
• 2.29. Japan: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.30. Japan: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
• 2.31. Japan: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
• 2.32. Japan: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.33. Germany: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
• 2.34. Germany: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
• 2.35. Germany: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
• 2.36. Germany: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
• 2.37. Germany: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.38. Germany: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
• 2.39. Germany: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
• 2.40. Germany: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.41. UK: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
• 2.42. UK: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
• 2.43. UK: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
• 2.44. UK: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
• 2.45. UK: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.46. UK: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
• 2.47. UK: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
• 2.48. UK: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.49. France: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
• 2.50. France: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
• 2.51. France: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
• 2.52. France: Historic & Projected Volume of incidence of Psoriatic Arthritis cases by Severity Type
• 2.53. France: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.54. France: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
• 2.55. France: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
• 2.56. France: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.57. Italy: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
• 2.58. Italy: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
• 2.59. Italy: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
• 2.60. Italy: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
• 2.61. Italy: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.62. Italy: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
• 2.63. Italy: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
• 2.64. Italy: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.65. Spain: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
• 2.66. Spain: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
• 2.67. Spain: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
• 2.68. Spain: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
• 2.69. Spain: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
• 2.70. Spain: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
• 2.71. Spain: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
• 2.72. Spain: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
• 3. PSORIATIC ARTHRITIS MARKET SIZE & OVERVIEW
• 3.1. 8MM: Historic & Projected Revenue of Psoriatic Arthritis
• 3.2. 8MM: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
• 3.3. 8MM: Major Approved Drugs in Psoriatic Arthritis
• 3.4. 8MM: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
• 3.5. US: Historic & Projected Revenue of Psoriatic Arthritis
• 3.6. US: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
• 3.7. US: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
• 3.8. China: Historic & Projected Revenue of Psoriatic Arthritis
• 3.9. China: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
• 3.10. China: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
• 3.11. Japan: Historic & Projected Revenue of Psoriatic Arthritis
• 3.12. Japan: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
• 3.13. Japan: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
• 3.14. Germany: Historic & Projected Revenue of Psoriatic Arthritis
• 3.15. Germany: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
• 3.16. Germany: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
• 3.17. UK: Historic & Projected Revenue of Psoriatic Arthritis
• 3.18. UK: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
• 3.19. UK: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
• 3.20. France: Historic & Projected Revenue of Psoriatic Arthritis
• 3.21. France: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
• 3.22. France: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
• 3.23. Italy: Historic & Projected Revenue of Psoriatic Arthritis
• 3.24. Italy: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
• 3.25. Italy: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
• 3.26. Spain: Historic & Projected Revenue of Psoriatic Arthritis
• 3.27. Spain: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
• 3.28. Spain: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
• 4. PSORIATIC ARTHRITIS MARKETED DRUGS OVERVIEW
• 4.1. Psoriatic Arthritis Marketed Drugs - An Overview
• 4.2. Psoriatic Arthritis Marketed Drugs - Summary
• 5. PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW
• 5.1. Psoriatic Arthritis Pipeline Drugs - An Overview
• 5.2. Psoriatic Arthritis Pipeline Drugs - Snapshot
• 5.3. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot - By Disease type
• 5.4. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot - By Development Phase
• 5.5. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot - By Route of Administration
• 5.6. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot - By Mechanism of Action
• 5.7. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot - By Molecule type
• 5.8. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot - By Geography type
• 6. PSORIATIC ARTHRITIS CLINICAL TRIALS OVERVIEW
• 6.1. Psoriatic Arthritis Clinical Trials Overview Snapshot
• 6.2. Psoriatic Arthritis Clinical Trials Overview - By Recruitment Status
• 6.3. Psoriatic Arthritis Clinical Trials Overview - By Product type
• 6.4. Psoriatic Arthritis Clinical Trials Overview - By Route of Administration
• 6.5. Psoriatic Arthritis Clinical Trials Overview - By Molecule type
• 6.6. Psoriatic Arthritis Clinical Trials Overview - By Geography type
• 7. PSORIATIC ARTHRITIS MARKET DYNAMICS
• 7.1. Psoriatic Arthritis Therapeutics Market Drivers
• 7.2. Psoriatic Arthritis Therapeutics Market Constraints
• 7.3. Psoriatic Arthritis Therapeutics Market Trends
• 8. PSORIATIC ARTHRITIS COMPETITIVE LANDSCAPE
• 8.1. Psoriatic Arthritis Competitive Landscape - Marketed Drugs
• 8.2. Key Company Profiles
• 8.3. Other Key Company Profiles
• 8.4. Competitive Scenario of Psoriatic Arthritis therapeutics market
• 8.5. Key Company Profile Snapshot
• 8.6. Other Key Company Profile Snapshot
• 8.7. Psoriatic Arthritis Competitive Landscape - Pipeline Drugs
• 8.8. Key Emerging Company Profiles
• 8.9. Other Key Emerging Company Profiles
• 8.10. Key Company Profile Snapshot
• 9. PSORIATIC ARTHRITIS MISCELLANEOUS
• 9.1. Key Tentative Drug Approvals Timeline
• 9.2. Key Regulatory Designations
• 9.3. Key Milestones
• 9.4. Deals & Collaborations
• 9.5. Inactive/Discontinued/Dormant Products
• 10. APPENDIX
• 10.1. About Arizton
• 10.2. Research Methodology
• 10.3. List of Abbreviations